Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Invest Dermatol. 2018 Feb 13;138(7):1539–1545. doi: 10.1016/j.jid.2018.01.032

Figure 1. Clinical progression of therapeutic response to Tofacitinib and relapse after discontinuation.

Figure 1.

(a) Relapse after treatment was stopped on week 24. (b) Relapse after treatment was stopped on week 50.